The systemic levels of C3a, C4a and C5a in different types of nAMD (e.g. CNV, RAP, PCV and fibrosis) or in different anti-VEGF therapy responder groups have not been investigated before, and such studies are important as different immunomechanisms may be involved in different types of nAMD. The gene discussed is C3; the disease is fibrosis.